Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NVAX |
---|---|---|
09:32 ET | 137673 | 12.67 |
09:34 ET | 14841 | 12.68 |
09:36 ET | 23810 | 12.73 |
09:38 ET | 22307 | 12.75 |
09:39 ET | 40319 | 12.958 |
09:41 ET | 37226 | 12.9099 |
09:43 ET | 65288 | 12.78 |
09:45 ET | 21209 | 12.79 |
09:48 ET | 10530 | 12.75 |
09:50 ET | 2732 | 12.77 |
09:52 ET | 9038 | 12.79 |
09:54 ET | 18151 | 12.8595 |
09:56 ET | 13215 | 12.765 |
09:57 ET | 45237 | 12.84 |
09:59 ET | 25207 | 12.85 |
10:01 ET | 15877 | 12.765 |
10:03 ET | 15450 | 12.7402 |
10:06 ET | 9322 | 12.73 |
10:08 ET | 47960 | 12.74 |
10:10 ET | 24632 | 12.74 |
10:12 ET | 16763 | 12.68 |
10:14 ET | 14932 | 12.7197 |
10:15 ET | 10356 | 12.71 |
10:17 ET | 9926 | 12.68 |
10:19 ET | 7593 | 12.66 |
10:21 ET | 8975 | 12.661 |
10:24 ET | 14081 | 12.67 |
10:26 ET | 16210 | 12.705 |
10:28 ET | 26779 | 12.675 |
10:30 ET | 22930 | 12.66 |
10:32 ET | 12185 | 12.73 |
10:33 ET | 25277 | 12.75 |
10:35 ET | 14572 | 12.7301 |
10:37 ET | 9170 | 12.72 |
10:39 ET | 9551 | 12.72 |
10:42 ET | 17199 | 12.78 |
10:44 ET | 7241 | 12.695 |
10:46 ET | 15842 | 12.675 |
10:48 ET | 11037 | 12.71 |
10:50 ET | 5990 | 12.7 |
10:51 ET | 20257 | 12.7883 |
10:53 ET | 16203 | 12.815 |
10:55 ET | 30946 | 12.885 |
10:57 ET | 60675 | 13.0201 |
11:00 ET | 35316 | 13.035 |
11:02 ET | 73059 | 13.0355 |
11:04 ET | 42086 | 13.025 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Novavax Inc | 1.8B | -4.1x | --- |
PTC Therapeutics Inc | 2.4B | -4.0x | --- |
ACADIA Pharmaceuticals Inc | 2.7B | -1,243.2x | --- |
Azenta Inc | 2.8B | -18.9x | --- |
P3 Health Partners Inc | 154.9M | -0.9x | --- |
Catalyst Pharmaceuticals Inc | 1.9B | 29.2x | --- |
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8B |
---|---|
Revenue (TTM) | $996.6M |
Shares Outstanding | 140.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-3.18 |
Book Value | $-5.14 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.